Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1991-12-16
|
pubmed:abstractText |
Despite the well-documented efficacy of lovastatin, a wide inter-individual variation in treatment responses has been observed. The aim of the present study was to investigate the possible roles of apolipoprotein E (apo E) phenotype and apolipoprotein B (apo B) XbaI genotype on this variation. The apo E phenotype was determined in 232 subjects (78 cases of familial hypercholesterolaemia [FH] and 154 cases of non-familial hypercholesterolaemia [non-FH]) and the apo B XbaI genotype was determined in 211 subjects (67 cases of FH, 144 cases of non-FH). Depending on their baseline total serum cholesterol levels, these patients used a starting dose of lovastatin of either 20 or 40 mg nightly. After 6 weeks of therapy, slightly but significantly smaller reductions in LDL-cholesterol were observed in patients with the E4/3 phenotype compared with those with the E3/3 phenotype in non-FH with lovastatin 20 mg (-20 vs. -28%; P = 0.043) and in total cholesterol in FH with lovastatin 40 mg (-23 vs. -27%; P = 0.023). No significant differences were found in non-FH patients starting with lovastatin, 40 mg. After doubling of the lovastatin doses, all treatment responses became similar among apo E phenotypes. Moreover, when all patients using lovastatin 40 mg either at 6 or 12 weeks were pooled (n = 224), no differences in treatment responses were observed between the E3/2, E3/3, E4/3 and E4/4 phenotypes. The apo B XbaI genotype did not affect the hypocholesterolaemic efficacy of lovastatin in any of the patient groups. Thus our results indicate that inter-individual variation in the treatment response to lovastatin in both familial and non-familial hypercholesterolaemia is mainly due to factors other than the apo E phenotype or apo B XbaI genotype.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins B,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins E,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyribonucleases, Type II...,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin,
http://linkedlifedata.com/resource/pubmed/chemical/endodeoxyribonuclease XBAI
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0954-6820
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
230
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
397-405
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1940775-Adult,
pubmed-meshheading:1940775-Aged,
pubmed-meshheading:1940775-Apolipoproteins B,
pubmed-meshheading:1940775-Apolipoproteins E,
pubmed-meshheading:1940775-Deoxyribonucleases, Type II Site-Specific,
pubmed-meshheading:1940775-Female,
pubmed-meshheading:1940775-Genotype,
pubmed-meshheading:1940775-Humans,
pubmed-meshheading:1940775-Hypercholesterolemia,
pubmed-meshheading:1940775-Hyperlipoproteinemia Type II,
pubmed-meshheading:1940775-Lovastatin,
pubmed-meshheading:1940775-Male,
pubmed-meshheading:1940775-Middle Aged,
pubmed-meshheading:1940775-Phenotype,
pubmed-meshheading:1940775-Polymorphism, Genetic
|
pubmed:year |
1991
|
pubmed:articleTitle |
Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
|
pubmed:affiliation |
First Department of Medicine, University of Helsinki, Finland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|